Pulmonary rehabilitation for people with COPD who also have heart or stroke-related vascular disease
Official title: Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT07090200 · Data updated 2026-11-12
We will test if adding a three-month pulmonary rehabilitation program to usual care helps adults with COPD who also have cardiovascular or cerebrovascular disease reduce flare-ups and improve breathing and quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50000 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | July 31, 2028 |
| Study ends | July 31, 2028 |
| Registry record updated | July 29, 2025 |
| Trial ID | NCT07090200 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with diagnosed COPD and coexisting cardiovascular or cerebrovascular disease who can consent and commit to the three-month program and follow-up.
✕Probably not a fit
Patients with severe unstable or life-threatening conditions, severe mental illness, pregnant or breastfeeding women, or those unable or unwilling to comply with follow-up are unlikely to benefit or may be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with COPD and coexisting cardiovascular or cerebrovascular disease will be screened, diagnosed, and randomized 1:1 to either routine care or pulmonary rehabilitation plus usual care. The pulmonary rehabilitation group will receive a structured exercise program alongside guideline-directed medications, while the routine group will receive standard pharmacological and non-pharmacological treatments per GOLD recommendations. Key outcomes—annual exacerbation frequency, COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), and lung ventilation and diffusion measures—will be collected and compared one year after the three-month intervention. The project also aims to develop and promote a 'trinity' rehabilitation management model for COPD patients with cardiovascular and cerebrovascular comorbidities.
Why it matters
Potential benefit: If effective, this approach could lower COPD exacerbations, improve symptoms and quality of life, and provide a structured rehabilitation model for patients with heart or cerebrovascular comorbidity.
How similar studies have gone: Pulmonary rehabilitation is an established therapy that improves symptoms and quality of life in COPD generally, but its targeted use and the proposed integrated 'trinity' management model for patients with cardiovascular or cerebrovascular comorbidity are less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Committed to adhering to the study protocol and cooperating with the implementation of the entire research process. 2. Aged 18 years or older, regardless of gender. 3. Signed informed consent form. Exclusion Criteria: 1. Individuals with severe mental illness. 2. Individuals assessed by medical personnel as having a disease that requires immediate hospitalization or a severe, uncontrollable condition that is life-threatening in the short term. 3. Women who are pregnant, breastfeeding, or using inappropriate contraception methods. 4. Individuals who refuse to cooperate with follow-up questionnaires or specimen collection. 5. Patients currently participating in other interventional clinical drug trials.
Where it's running
-
Union hospital, Tongji Medical college, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Guanzhou Ma
- Email: maguanzhouxiehe@126.com
- Phone: 86+13554024801
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding cardiovascular risks in young adults born to hypertensive pregnancies
This study is looking at the heart health of young adults in their 20s and 30s who were born to mothers with high blood pressure during pregnancy to see if it affects their risk of heart problems later on.
-
Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery
This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Low-Dose CBCT AI Model for Interventions
This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.